Volume 31, Number 5—May 2025
Synopsis
Comprehensive Survival Analysis of Alveolar Echinococcosis Patients, University Hospital Zurich, Zurich, Switzerland, 1973–2022
Table 2
Treatments used for alveolar echinococcosis patients, University Hospital Zurich, Zurich, Switzerland, 1973–2022*
Treatment | Value |
---|---|
No. patients |
334 |
Surgical therapy | 151 (45.2) |
Time to surgery, mo, median (IQR) | 1 (0–4) |
Surgery aim | |
Palliative | 25 (7.5) |
After >12 mo | 5 (1.5) |
Curative | 126 (37.7) |
After >12 mo | 5 (1.5) |
Resection margins | |
R0 | 105 (31.4) |
R1 | 21 (6.3) |
Surgery type | |
Segmentectomy | 51 (15.3) |
Hemihepatectomy | 53 (15.9) |
Extended hemihepatectomy | 17 (5.1) |
Liver transplantation | 3 (0.9) |
Nonhepatic surgery |
2 (0.6) |
Benzimidazole drug therapy | 315 (94.3) |
Time to benzimidazole start, mo, median (IQR) | 1 (0–2) |
>12 mo | 17 (5.1) |
Benzimidazole drug type | |
Albendazole | 241 (72.2) |
Mebendazole | 74 (22.2) |
Clinical setting | |
After curatively intended surgery | 122 (36.5) |
R0 margin | 97 (29.0) |
Duration, mo, median (IQR) | 26 (23–31.5) |
R1 margin | 21 (6.3) |
Duration, mo, median (IQR) | 79 (44–152) |
Palliative surgery and nonresected | 212 (63.5) |
*Values are no. (%) except as indicated.
1These first authors contributed equally to this article.
Page created: March 11, 2025
Page updated: May 05, 2025
Page reviewed: May 05, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.